References

Modulation of multidrug-resistant multiple myeloma by cyclosporin

10.1016/0140-6736(92)92353-h · 1992 · External reference

Clinical trials of agents that reverse multidrug resistance

1993 · External reference

Induction of interleukin 2 messenger RNA inhibited by cyclosporin A

10.1126/science.6334364 · 1984 · External reference

Alteration of etoposide pharmacokinetics, and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance

10.1200/jco.1992.10.10.1635 · 1992 · External reference

Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blase cells from patients with previously untreated acute myeloid leukemia

10.1182/blood.v82.4.1288.1288 · 1993 · External reference

Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance

10.1200/jco.1992.10.10.1624 · 1992 · External reference

Phase I trial of carboplatin, and infusional cyclosporine in advanced malignancy

10.1200/jco.1995.13.9.2238 · 1995 · External reference

Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance

10.1200/jco.1994.12.4.835 · 1994 · External reference

Cyclosporin enhancement of cisplatin chemotherapy in patient with refractory gynecologic cancer

10.1002/1097-0142(19940101)73:1<196::aid-cncr2820730134>3.0.co;2-f · 1994 · External reference

Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients

1996 · External reference

Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: A phase II study

1996 · External reference

Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population

10.1200/jco.1992.10.4.513 · 1992 · External reference

GOG Common Toxicity Criteria, Appendix 3

1996 · External reference

Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines

10.1200/jco.1996.14.6.1957 · 1996 · External reference

P-glycoproteins in pathology: The multidrug resistance gene family in humans

10.1016/0046-8177(90)90073-e · 1990 · External reference

Cyclosporin A enhances paclitaxel toxicity against leukemia and respiratory epithelial cancers

1997 · External reference

Modification of cytotoxic drug resistance by non-immunosuppressive cyclosporins

10.1038/bjc.1988.55 · 1988 · External reference

Molecular basis of cisplatin resistance in human carcinomas: Model systems and patients

1989 · External reference

Reversal of cisplatinum resistance by cyclosporin A in xenografts of fresh human ovarian carcinoma

1988 · External reference

Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells

10.1016/s0021-9258(19)38588-6 · 1990 · External reference

Reversion of multidrug resistance in the p-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme

10.1038/bjc.1994.286 · 1994 · External reference

Phase II study of combining vinblastine and cyclosporin A to circumvent multidrug resistance in renal cell cancer

10.1093/oxfordjournals.annonc.a057941 · 1991 · External reference

Unresolved reference

External reference

Biochemical modulation of anthracycline resistance(MDR) in acute leukemia with cyclosporin A (CSA)

1992 · External reference

Evaluation of cisplatin, and cyclosporin A in recurrent platinum-resistant ovarian cancer: A phase II study of the Gynecologic Oncology Group

10.1006/gyno.1997.4887 · 1998 · External reference

Cyclosporine induces cancer progression by a cell-autonomous mechanism

1999 · External reference

Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin

10.1016/0277-5379(91)90435-g · 1991 · External reference

In vivo circumvention of p-glycoprotein mediated multidrug resistance of tumor cells with SDZ PSC-833

1991 · External reference

Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents

10.1097/00001813-199404000-00015 · 1994 · External reference